Trials / Conditions / Tumor Lysis Syndrome

Tumor Lysis Syndrome

10 registered clinical trials studyying Tumor Lysis Syndrome.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome NCT04745910	M.D. Anderson Cancer Center	Phase 4
Terminated	Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults NCT03605212	Menarini Group	Phase 1 / Phase 2
Completed	Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies NCT01724528	Menarini Group	Phase 3
Terminated	Elitek (Rasburicase) Immuno-Monitoring Study NCT01097369	Sanofi	—
Completed	Rasburicase in Patients at Risk for Tumor Lysis Syndrome NCT00628628	M.D. Anderson Cancer Center	Phase 2
Completed	Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS NCT00360438	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients NCT00186940	St. Jude Children's Research Hospital	—
Completed	Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome NCT00230178	Sanofi	Phase 3
Completed	Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patie NCT00230217	Sanofi	Phase 4
Completed	Fasturtec TLS Treatment / Prophylysis NCT00651911	Sanofi	Phase 4